Related Experiment Video
Updated: Apr 8, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
21.3K
Volumetric-modulated arc therapy planning using multicriteria optimization for localized prostate cancer
Sarah Ghandour1, Oscar Matzinger, Marc Pachoud
1Cancer Center - Radiotherapy Department, Riviera-Chablais Hospital. sarah.ghandour@hopitalrivierachablais.ch.
Journal of Applied Clinical Medical Physics
|June 24, 2015
Summary
The new multicriteria optimization (MCO) algorithm in VMAT planning reduces treatment time for prostate cancer patients without compromising dosimetric quality. This efficient VMAT-MCO system ensures accurate dose delivery and spares healthy tissues.
Area of Science:
- Radiation Oncology
- Medical Physics
- Cancer Treatment
Background:
- Volumetric-modulated arc therapy (VMAT) is a widely used technique for delivering precise radiation doses.
- Multicriteria optimization (MCO) algorithms aim to improve treatment planning efficiency and plan quality.
- Evaluating new algorithms is crucial for advancing radiation therapy techniques.
Purpose of the Study:
- To assess the clinical efficacy of the VMAT multicriteria optimization (MCO) algorithm in the RayStation treatment planning system (TPS).
- To determine if VMAT-MCO can reduce treatment planning time while maintaining high dosimetric quality for prostate cancer patients.
- To evaluate the impact of technical parameters on the accuracy of dose delivery with VMAT-MCO.
Main Methods:
- Nine prostate cancer patients previously treated with VMAT (rayArc/DMPO) were replanned using VMAT-MCO.
- Dosimetric plan quality was assessed using conformity metrics (CI, HI) for target coverage and organ-at-risk sparing.
- Treatment planning time, monitor units, and quality assurance passing rates (Delta4 phantom) were evaluated.
- The influence of constraint leaf motion (CLM) and maximum arc delivery time (T) on dose accuracy was investigated.
Main Results:
- VMAT-MCO produced plans comparable to rayArc for PTV, bladder, and rectum constraints (V95%, D1%, CI, HI).
- A significant dose reduction was observed for femoral heads and healthy tissues with VMAT-MCO compared to rayArc.
- Optimal technical parameters (CLM=0.5 cm/°, T=72 s) ensured accurate dose delivery on an Elekta Versa HD linear accelerator.
- Treatment planning time was significantly reduced using VMAT-MCO.
Conclusions:
- The VMAT-MCO algorithm is clinically viable for prostate cancer treatment.
- VMAT-MCO enhances planning process efficiency by reducing treatment planning time.
- The dosimetric quality of VMAT-MCO plans is comparable to existing methods, with improved sparing of certain organs at risk.
